These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

198 related articles for article (PubMed ID: 35774429)

  • 21. Systemic treatment of malignant pleural mesothelioma: new agents in clinical trials raise hope of relevant improvements.
    Christoph DC; Eberhardt WE
    Curr Opin Oncol; 2014 Mar; 26(2):171-81. PubMed ID: 24441503
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The Evolving Role of Immune-Checkpoint Inhibitors in Malignant Pleural Mesothelioma.
    Borgeaud M; Kim F; Friedlaender A; Lococo F; Addeo A; Minervini F
    J Clin Med; 2023 Feb; 12(5):. PubMed ID: 36902544
    [TBL] [Abstract][Full Text] [Related]  

  • 23. New horizons from immunotherapy in malignant pleural mesothelioma.
    Calabrò L; Rossi G; Maio M
    J Thorac Dis; 2018 Jan; 10(Suppl 2):S322-S332. PubMed ID: 29507802
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Benefits and Challenges of Inhibiting EZH2 in Malignant Pleural Mesothelioma.
    Al Khatib MO; Pinton G; Moro L; Porta C
    Cancers (Basel); 2023 Feb; 15(5):. PubMed ID: 36900330
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Epigenetic Alterations and Biomarkers for Immune Checkpoint Inhibitors-Current Standards and Future Perspectives in Malignant Pleural Mesothelioma Treatment.
    Yoshikawa Y; Kuribayashi K; Minami T; Ohmuraya M; Kijima T
    Front Oncol; 2020; 10():554570. PubMed ID: 33381446
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Nivolumab Immunotherapy in Malignant Mesothelioma: A Case Report Highlighting a New Opportunity for Exceptional Outcomes.
    Jones RG; Karthik F; Dugar A; Kanagarajan K; Desai K; Bhandari M
    Am J Case Rep; 2018 Jul; 19():783-789. PubMed ID: 29970876
    [TBL] [Abstract][Full Text] [Related]  

  • 27. NIPU: a randomised, open-label, phase II study evaluating nivolumab and ipilimumab combined with UV1 vaccination as second line treatment in patients with malignant mesothelioma.
    Haakensen VD; Nowak AK; Ellingsen EB; Farooqi SJ; Bjaanæs MM; Horndalsveen H; Mcculloch T; Grundberg O; Cedres SM; Helland Å
    J Transl Med; 2021 May; 19(1):232. PubMed ID: 34059094
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The value of pemetrexed for the treatment of malignant pleural mesothelioma: a comprehensive review.
    Boons CC; VAN Tulder MW; Burgers JA; Beckeringh JJ; Wagner C; Hugtenburg JG
    Anticancer Res; 2013 Sep; 33(9):3553-61. PubMed ID: 24023280
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Systemic treatment in patients with malignant pleural mesothelioma - real life experience.
    Ziółkowska B; Cybulska-Stopa B; Papantoniou D; Suwiński R
    BMC Cancer; 2022 Apr; 22(1):432. PubMed ID: 35443624
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Current evidence and future perspectives of immune-checkpoint inhibitors in unresectable malignant pleural mesothelioma.
    Hotta K; Fujimoto N
    J Immunother Cancer; 2020 Feb; 8(1):. PubMed ID: 32098830
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Immune checkpoint inhibitors for unresectable malignant pleural mesothelioma.
    Metro G; Signorelli D; Pizzutilo EG; Giannetta L; Cerea G; Garaffa M; Friedlaender A; Addeo A; Mandarano M; Bellezza G; Roila F
    Hum Vaccin Immunother; 2021 Sep; 17(9):2972-2980. PubMed ID: 34003722
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Repurposing therapeutics for malignant pleural mesothelioma (MPM) - Updates on clinical translations and future outlook.
    Kulkarni NS; Gupta V
    Life Sci; 2022 Sep; 304():120716. PubMed ID: 35709894
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Malignant pleural mesothelioma.
    Chen SE; Pace MB
    Am J Health Syst Pharm; 2012 Mar; 69(5):377-85. PubMed ID: 22345416
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Progress in treatment for malignant pleural mesothelioma].
    Wang YY; He YL; Chi YJ; Zhai XY; An TT; Li JJ; Zhuo ML; Zhao J; Wang ZP
    Zhonghua Jie He He Hu Xi Za Zhi; 2022 Jan; 45(1):111-115. PubMed ID: 35000316
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Retreatment of recurrent malignant pleural mesothelioma with cisplatin and pemetrexed.
    Hayashi H; Okamoto I; Ichikawa Y; Miyazaki M; Yoshioka H; Kunimasa K; Nakagawa K
    Int J Clin Oncol; 2010 Oct; 15(5):497-9. PubMed ID: 20224880
    [TBL] [Abstract][Full Text] [Related]  

  • 36. In Vitro Characterization of Cisplatin and Pemetrexed Effects in Malignant Pleural Mesothelioma 3D Culture Phenotypes.
    Papazoglou ED; Jagirdar RM; Kouliou OA; Pitaraki E; Hatzoglou C; Gourgoulianis KI; Zarogiannis SG
    Cancers (Basel); 2019 Sep; 11(10):. PubMed ID: 31569615
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Pleural Mesothelioma in the Era of Immunotherapy.
    Chevallier M; Kim F; Friedlaender A; Addeo A
    Clin Med Insights Oncol; 2023; 17():11795549231178173. PubMed ID: 37492425
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Pemetrexed-loaded nanoparticles targeted to malignant pleural mesothelioma cells: an in vitro study.
    Cova E; Pandolfi L; Colombo M; Frangipane V; Inghilleri S; Morosini M; Mrakic-Sposta S; Moretti S; Monti M; Pignochino Y; Benvenuti S; Prosperi D; Stella G; Morbini P; Meloni F
    Int J Nanomedicine; 2019; 14():773-785. PubMed ID: 30774332
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Pemetrexed: a multitargeted antifolate.
    Rollins KD; Lindley C
    Clin Ther; 2005 Sep; 27(9):1343-82. PubMed ID: 16291410
    [TBL] [Abstract][Full Text] [Related]  

  • 40. SKP2 drives the sensitivity to neddylation inhibitors and cisplatin in malignant pleural mesothelioma.
    Salaroglio IC; Belisario DC; Bironzo P; Ananthanarayanan P; Ricci L; Digiovanni S; Fontana S; Napoli F; Sandri A; Facolmatà C; Libener R; Comunanza V; Grosso F; Gazzano E; Leo F; Taulli R; Bussolino F; Righi L; Papotti MG; Novello S; Scagliotti GV; Riganti C; Kopecka J
    J Exp Clin Cancer Res; 2022 Feb; 41(1):75. PubMed ID: 35197103
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.